Nektar Therapeutics (NKTR)
0.81
-0.03 (-3.57%)
At close: Mar 03, 2025, 3:59 PM
0.85
4.94%
After-hours: Mar 03, 2025, 07:58 PM EST
No 1D chart data available
| Bid | 0.81 |
| Market Cap | 148.6M |
| Revenue (ttm) | 82.1M |
| Net Income (ttm) | -148.36M |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | -0.98 |
| Analyst | Buy |
| Ask | 0.85 |
| Volume | 1,121,046 |
| Avg. Volume (20D) | 2,237,818 |
| Open | 0.84 |
| Previous Close | 0.84 |
| Day's Range | 0.80 - 0.85 |
| 52-Week Range | 0.65 - 1.93 |
| Beta | 0.58 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and a...
Industry Biotechnology
Sector Healthcare
IPO Date May 3, 1994
Employees 137
Stock Exchange NASDAQ
Ticker Symbol NKTR
Website https://www.nektar.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 396.52% from the latest price.
Buy 80.00%
Hold 20.00%
Sell 0.00%
Next Earnings Release
Nektar Therapeutics is scheduled to release its earnings on Mar 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+3.55%
Nektar Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+8.13%
Nektar Therapeutics shares are trading higher after the company announced it will sell its commercial PEGylation reagent manufacturing business to Ampersand Capital Partners.
